Design and optimization of hybrid of 2,4-diaminopyrimidine and arylthiazole scaffold as anticancer cell proliferation and migration agents.
Wenbo Zhou, Anling Huang, Yong Zhang, Qingxiang Lin, Weikai Guo, Zihua You, Zhengfang Yi, Mingyao Liu, Yihua Chen
文献索引:Eur. J. Med. Chem. 96 , 269-80, (2015)
全文:HTML全文
摘要
Therapeutics of metastatic or triple-negative breast cancer are still challenging in clinical. Herein we demonstrated the design and optimization of a series of hybrid of 2,4-diaminopyrimidine and arylthiazole derivatives for their anti-proliferative properties against two breast cancer cell lines (MCF-7 as human breast cancer and MDA-MB-231 as triple-negative breast cancer). More importantly, some of those compounds with potent antiproliferative activities also indicated excellent inhibitory activities against MDA-MB-231 cell migration. These results suggested that the new series of hybridation of aryl-thiazoles and aminopyrimidines could be identified and developed as novel highly potential anticancer agents against the triple-negative breast cancer as well as metastatic one in the future. Copyright © 2015 Elsevier Masson SAS. All rights reserved.
相关化合物
相关文献:
2015-12-01
[Neuropharmacology 99 , 422-31, (2015)]
2015-03-01
[Acta Crystallogr. C Struct. Chem. 71(Pt 3) , 229-38, (2015)]
2009-03-01
[Anal. Bioanal. Chem 393(6-7) , 1709-18, (2009)]
2007-06-01
[Antimicrob. Agents Chemother. 51(6) , 2268-73, (2007)]
2010-04-16
[J. Biol. Chem. 285(16) , 12101-8, (2010)]